Close Menu

NEW YORK – Hengrui Therapeutics and Thermo Fisher Scientific announced on Monday an agreement to advance a companion diagnostic for identifying lung cancer patients with HER2 mutations who are eligible to receive Jiangsu Hengrui Medicine's treatment pyrotinib.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.